Guidelines for preclinical animal research in ALS/MND: A consensus meeting.
The development of therapeutics for ALS/MND is largely based on work in experimental animals carrying human SOD mutations. However, translation of apparent therapeutic successes from in vivo to the human disease has proven difficult and a considerable amount of financial resources has been apparently wasted. Standard operating procedures (SOPs) for preclinical animal research in ALS/MND are urgently required. Such SOPs will help to establish SOPs for translational research for other neurological diseases within the next few years. To identify the challenges and to improve the research methodology, the European ALS/MND group held a meeting in 2006 and published guidelines in 2007 (1). A second international conference to improve the guidelines was held in 2009. These second and improved guidelines are dedicated to the memory of Sean F. Scott.
Ludolph
Albert C
AC
Department of Neurology, University of Ulm, Germany. albert.ludolph@rku.de <albert.ludolph@rku.de>
Bendotti
Caterina
C
Blaugrund
Eran
E
Chio
Adriano
A
Greensmith
Linda
L
Loeffler
Jean-Philippe
JP
Mead
Richard
R
Niessen
Heiko G
HG
Petri
Susanne
S
Pradat
Pierre-Francois
PF
Robberecht
Wim
W
Ruegg
Markus
M
Schwalenstöcker
Birgit
B
Stiller
Detlev
D
van den Berg
Leonard
L
Vieira
Fernando
F
von Horsten
Stephan
S
D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy*; D000818:Animals; D032921:Consensus; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical / Q000379:methods* / Q000592:standards*; D017408:Guidelines as Topic